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Abstract
Background Epidemiological studies suggest a potential
role for obesity and determinants of adult stature in prostate
cancer risk and mortality, but the relationships described in
the literature are complex. To address uncertainty over the
causal nature of previous observational findings, we
investigated associations of height- and adiposity-related
genetic variants with prostate cancer risk and mortality.
Methods We conducted a case–control study based on
20,848 prostate cancers and 20,214 controls of European
ancestry from 22 studies in the PRACTICAL consortium.
We constructed genetic risk scores that summed each
man’s number of height and BMI increasing alleles across
multiple single nucleotide polymorphisms robustly asso-
ciated with each phenotype from published genome-wide
association studies.
Results The genetic risk scores explained 6.31 and 1.46 %
of the variability in height and BMI, respectively. There was
only weak evidence that genetic variants previously associ-
ated with increased BMI were associated with a lower
prostate cancer risk (odds ratio per standard deviation
PRACTICAL consortium is provided in appendix section.
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increase in BMI genetic score 0.98; 95 % CI 0.96, 1.00;
p = 0.07). Genetic variants associated with increased height
were not associatedwith prostate cancer incidence (OR0.99;
95 % CI 0.97, 1.01; p = 0.23), but were associated with an
increase (OR 1.13; 95 % CI 1.08, 1.20) in prostate cancer
mortality among low-grade disease (p heterogeneity, low vs.
high grade \0.001). Genetic variants associated with
increased BMI were associated with an increase (OR 1.08;
95 % CI 1.03, 1.14) in all-cause mortality among men with
low-grade disease (p heterogeneity = 0.03).
Conclusions We found little evidence of a substantial
effect of genetically elevated height or BMI on prostate
cancer risk, suggesting that previously reported observa-
tional associations may reflect common environmental
determinants of height or BMI and prostate cancer risk.
Genetically elevated height and BMI were associated with
increased mortality (prostate cancer-specific and all-cause,
respectively) in men with low-grade disease, a potentially
informative but novel finding that requires replication.
Keywords Height  Body mass index  Prostate cancer 
Mendelian randomization  Single nucleotide
polymorphisms  Instrumental variables analysis
Introduction
Prostate cancer is the most common male cancer in Europe
and North America, but the robust identification of poten-
tially modifiable risk factors has proven elusive [1]. Epi-
demiological studies suggest a potential role for obesity
[2–5] and determinants of adult stature [6], but the
relationships described in the literature are complex [7–9].
Inverse associations have generally been observed between
adiposity and localized prostate cancer, but associations are
largely positivewith advanced or high-grade [2, 10] and fatal
[3] cancer and may vary in direction depending on whether
obesity was observed in early ormiddle to late adulthood [4].
Adult stature is generally positively associated with prostate
cancer, although associations may be stronger for fatal [11]
or high- compared with low-grade disease [6].
The explanation for these associations is unclear. Obser-
vations regarding obesity could be due to confounding by
common causes of both obesity and prostate cancer (e.g.,
calorie and dietary fat intake) [12]; the mitogenic hormones
insulin and insulin-like growth factor-I [13, 14]; delayed
detection in obese men [8, 9]; or a real biological effect [15].
Observed height associations could reflect early-life envi-
ronmental (e.g., fetal, dietary, social, hormones, and psy-
chological circumstances) or shared genetic contributions to
stature and prostate cancer risk [16–18].
Genetic epidemiological studies are less susceptible to
confounding than observational epidemiology. This is
because conditional on population structure, genetic variants
are more likely to be independent of later environment and
lifestyle factors [19]; they are also unlikely to be affected by
reverse causation. Thus, the existence of genetic variation in
obesity and height can provide robust evidence about how
associations of phenotypes, in this case obesity and height,
with diseases arise [15].We previously reported that a single
nucleotide polymorphism (SNP) associated with obesity
(FTO rs9939609-A) was inversely associated with low-
grade prostate cancer (odds ratio, OR 0.90 per A allele; 95 %
CI 0.81, 0.99; p = 0.03), but positively associatedwith high-
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grade cancer (OR 1.16; 0.99, 1.37; p = 0.07) [15]. These
data suggest that the comparable observational associations
between adiposity phenotypes and prostate cancer outcomes
are not confounded. However, the evidence for these effects
was weak, originating from a single study of moderate size
(1,550 cases) using only a single variant, and there is no
evidence we are aware of linking genetic variation in height
with prostate cancer. The results, therefore, require confir-
mation and extension in larger datasets, using height- and
additional adiposity-related genetic variants.
Our aim was to use genetic variation in height and body
mass index (BMI) as unconfounded exposures to investi-
gate the causal associations of obesity and stature with
prostate cancer risk and outcomes (Mendelian randomiza-
tion [20]). Instead of the single-variant, single-sample
approach used previously, we employ a more powerful
two-sample, multiple-variant approach [21, 22] that com-
bines several polymorphisms (based on confirmed genetic
variant-intermediate phenotype associations [23, 24]) into
genetic risk scores in order to explain more of the variance
in BMI and height exposures and thus increase power and
avoid weak instrument bias [21].
Methods
Participants in this study were men of European genotypic
ancestry from 22 independent studies contributing to the
international PRACTICAL Consortium (PRostate cancer
AssoCiation group To Investigate Cancer-Associated
aLterations in the genome, http://www.practical.ccge.
medschl.cam.ac.uk) [25, 26]. The individual studies are
described at http://www.nature.com/ng/journal/v45/n4/
extref/ng.2560-S1.pdf, with summary data in Table 1. Of the
studies within the PRACTICAL Consortium at the time of
data extraction, we excluded the EPIC-Norfolk, CAPS, and
SEARCH studies (involving 3,005 cases and 2,825 controls),
because they were included in the genome-wide studies that
originally detected the height and BMI genetic variants [23,
24]. Cancers were categorized as low grade (Gleason
score B 6) or high grade (Gleason score C 7) and localized
(T1 or T2 on TNM staging, or if not available, ‘‘localized’’ on
SEER staging) or advanced (T3 or T4 on TNM staging, or if
not available, ‘‘regional’’ or ‘‘distant’’ on SEER staging). All
studies met the appropriate ethical criteria for each country in
accordancewith the principles embodied in theDeclaration of
Helsinki.
Genotyping
Genotyping was carried out using an Illumina Custom
Infinium genotyping array (iCOGS), designed for the
Collaborative Oncological Gene-environment Study
(COGS), and consisted of 211,155 SNPs (details at http://
ec.europa.eu/research/health/medical-research/cancer/fp7-
projects/cogs_en.html) [25, 26]. This array was devised to
evaluate genetic variants for associations with breast, ovar-
ian, and prostate cancer; 68,638 were specifically chosen for
their potential relevance to prostate cancer. The remaining
125,877 SNPs measured by the array were chosen for
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relevance to other cancers and common SNPs which had
been previously associated with any trait. Participants with
low call rates (\95 %) and high or low heterozygosity
(p\ 1 9 10-5) were excluded; 201,598 SNPs passed
quality control for the European ancestry samples. We used
these genotypic data to impute 2.6 million SNPs based on
the HapMap 2 CEU reference panel and using IMPUTE2
software [27]. We excluded poorly imputed SNPs
(R2\ 0.3).
Constructing genetic risk scores for BMI and height
We constructed genetic risk scores [21] for height and BMI
using 179 and 32 variants, respectively, previously reported
in genome-wide association studies (GWAS) to be asso-
ciated with height [23] and BMI [24]. We used allele
dosages from the imputation to construct the genetic risk
score. The dosages code each SNP continuously from 0 to
2, and the dosages across all SNPs are summed to estimate
Table 1 Clinical characteristics of the men in each of the studies contributing to the PRACTICAL consortium (n = 41,062)
Study Country n Mean %
Controls Cases Age at
diagnosis
(years)
PSA at
diagnosis
(ng/ml)
Screen
detectedb
(%)
Family history
prostate cancer
Gleason
score
8–10
Advanced
stage (T3 or
T4)
Distant
spread
(SEER)
CPCS1 Denmark 2,771 848 69.5 48.0 0.0 8.2 35.0 – –
CPCS2 Denmark 1,009 265 64.9 36.0 0.0 14.7 10.6 – –
EPIC Europea 1,079 722 64.9 19.7 0.0 – 3.6 3.8 0.9
ESTHER Germany 318 313 65.5 58.7 61.9 8.9 9.1 26.4 3.4
FHCRC USA 730 761 59.7 16.1 – 21.7 10.4 – 2.6
IPO-Porto Portugal 66 183 59.3 8.3 82.8 20.0 15.8 64.5 0.0
MAYO USA 488 767 65.2 15.5 73.7 29.1 33.0 44.4 0.5
MCCS Australia 1,169 1,698 58.5 136.6 – 23.4 11.0 14.0 0.8
MEC USA 829 819 69.5 – – 13.0 36.0 – 2.8
MOFFITT USA 100 412 64.9 7.3 0.0 22.9 11.2 3.5 0.5
PCMUS Bulgaria 140 151 69.3 32.5 21.2 5.3 29.8 42.4 18.5
PPF-UNIS UK 176 244 68.9 32.0 – 25.3 10.9 25.7 9.0
Poland Poland 359 438 67.7 40.2 0.0 10.6 14.0 36.8 2.8
ProMPT UK 1 166 66.3 33.0 0.0 34.6 18.9 32.7 7.8
ProtecT UK 1,474 1,542 62.8 9.6 100.0 7.9 5.7 11.3 0.4
QLD/
ProsCan
Australia 87 186 61.3 6.7 – 36.2 4.0 0.0 0.0
STHMI Sweden 2,224 2,002 66.2 – – 20.2 10.2 14.2 1.6
TAMPERE Finland 2,413 2,753 68.2 69.1 46.8 – 15.4 21.0 7.3
UKGPCS UK 4,182 4,549 63.8 83.9 28.9 23.4 17.2 32.9 10.7
ULM Germany 354 601 63.8 19.1 – 44.9 15.5 39.9 1.1
UTAH USA 245 440 62.6 – – 51.4 16.1 – 4.7
WUGS USA 0 988 60.8 6.2 – 42.3 7.9 24.2 0.1
Studies: Copenhagen Prostate Cancer Study 1 (CPCS1); Copenhagen Prostate Cancer Study 2 (CPCS2); European Prospective Investigation Into
Cancer and Nutrition (EPIC); Epidemiological investigations of the chances of preventing, recognizing early and optimally treating chronic
diseases in an elderly population (ESTHER); Fred Hutchinson Cancer Research Center (FHCRC); Portuguese Oncology Institute, Porto (IPO-
Porto); Mayo Clinic (MAYO); Melbourne Collaborative Cohort Study (MCCS); Multiethnic Cohort Study (MEC); The Moffitt Group
(MOFFITT); Prostate Cancer study Medical University Sofia (PCMUS); Prostate Project Foundation-Postgraduate Medical School, Surrey (PPF-
UNIS); The Poland Group (Poland); Prostate cancer: Mechanisms of progression and Treatment (ProMPT); Prostate testing for cancer and
Treatment (ProtecT); Retrospective Queensland Study (QLD) and the Prostate Cancer Supportive Care and Patient Outcomes Project (ProsCan);
Stockholm 1 (STHMI); Finnish Genetic Predisposition to Prostate Cancer Study (TAMPERE); U.K. Genetic Prostate Cancer Study and The
Prostate Cancer Research Foundation Study (UKGPCS); Familial Prostate Cancer Study Ulm (ULM); UTAH Study (UTAH); Washington
University Genetics Study (WUGS)
a Germany, Greece, Italy, Netherlands, Spain, Sweden, Oxford
b Studies with 0 % screen detected are entirely based on clinically detected cases, and studies with no information about method of detection
have a missing value; 12,231 individuals have information of method of detection
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the number of height or BMI increasing risk alleles per
man. Each genetic variant was given a weight equal to the
effect of the variant on height or BMI reported by the
previous GWASs [23, 24]. The genetic risk score is
therefore a weighted sum of the estimated number of risk
alleles across several genotypes, which can improve the
precision of the results compared to an unweighted score
[21]. Supplementary Tables 1 and 2 provide details of the
variants used and weights assigned.
Statistical analysis
We estimated associations of the genetic risk scores with
measured height and BMI using linear regression based on
1,270 men without prostate cancer [i.e., prostate-specific
antigen (PSA) level\3.0 ng/ml or men with a raised PSA
but who were biopsy negative] from the ProtecT popula-
tion-based study [15, 28], one of the PRACTICAL studies
with the relevant phenotypic data in a well-defined control
group. We computed F statistics and R2 values (the pro-
portion of variation in height and BMI explained by the
genetic risk score) from the linear regression to evaluate
the strength of the genetic risk score instruments in a
population of men at increased risk of cancer. We had 82
and 78 % power to detect an odds ratio of 1.12 and 1.25 for
the effects of height and BMI on prostate cancer risk,
assuming a sample size of 41,062 and that the genetic risk
scores explained 6.31 and 1.46 % of the variation in height
and BMI, respectively [29].
We investigated associations of the phenotypes (height
and BMI) and the genetic risk scores (for height and BMI)
with measured covariables in the ProtecT cases to assess
whether the scores were likely to be independent of
potential environmental confounding factors and to assess
the potential for pleiotropy (genetic confounding). We
included the following potential confounders: diabetes;
occupation (managerial vs. nonmanagerial); exercise
(strenuous; moderate or strenuous, vs. light); alcohol intake
(three or more drinks a week vs. two or less); smoking
(passive, current, or ex-smoker vs. never); diagnostic PSA
level; and age at recruitment. We investigated whether the
scores predicted circulating insulin-like growth factor
(IGF-I) levels (a potential mechanism linking size with
prostate cancer [13, 14]) and benign prostatic hyperplasia
(a potential cause of detection bias [30]).
We assessed the relationship of the height and BMI
genetic risk scores with prostate cancer risk, stage, and
grade across all 22 eligible studies contributing to PRAC-
TICAL using logistic regression to compute ORs, with
robust standard errors to account for within-study cluster-
ing. The genetic risk score was standardized to mean zero
and standard deviation one, and the ORs were parameter-
ized as the change in outcome per standard deviation
increase in genetic risk score. In a secondary analysis, we
also computed ORs comparing the highest versus the
lowest quintile of each genetic risk score to illustrate the
differences in outcomes between the extremes of the BMI
or height allele score distributions. This reduced form, the
association of the instrument (the genetic risk score) with
the outcome, is a valid test of the direction of the effect of a
phenotype on an outcome [31, 32]. We investigated
between-study heterogeneity by estimating the logistic
regressions individually for each study and using the Stata
metan command to estimate the I2 statistic assuming a
fixed-effect model. As we found little evidence of hetero-
geneity, we report the ORs from the logistic regression
analyses conducted across the 22 included studies.
We calculated ORs for all prostate cancers and then
separately for localized versus advanced and low-grade
(Gleason score B 6) versus high-grade (Gleason
score C 7) cancers. Among men with prostate cancer
(case-only analysis), we estimated associations of the
standardized height and BMI weighted genetic risk scores
with all-cause and prostate cancer-specific mortality using
Cox proportional hazards regression, with age at diagnosis
as the start date and age at death or final follow-up time-
point as the exit date, with standard errors clustered by
study (there was no evidence that the proportional hazards
assumption was violated). We tested for heterogeneity in
association of the genetic risk scores with localized versus
advanced and low- versus high-grade prostate cancer risk
using a multivariate logistic regression. We tested for
heterogeneity in the association of the genetic risk scores
and survival of patients with localized versus advanced and
low versus high grade using the test proposed by Altman
and Bland [33].
Sensitivity analyses
We assessed the potential for pleiotropy, since it is possible
that variants identified in the genome-wide scans are not
specific for height or BMI and have effects on the prostate
cancer outcomes independent of their effects on the
exposures (height or BMI) [34]. If the no-effect modifica-
tion assumption holds, similar instrumental variable esti-
mates acquired using independent instruments would
provide suggestive evidence against an influence of pleio-
tropic effects, as it is unlikely that they have shared
pleiotropy [21, 35]. Therefore, as a sensitivity analysis we
tested for evidence of heterogeneity across different SNPs
for each of our baseline results which differed from the
null. We generated two independent genetic instruments
for BMI using (1) rs1558902 in FTO, the individual SNP
with the largest effect size in the meta-analysis of GWASs
for BMI [24] and (2) a weighted allelic score constructed
from the remaining BMI-associated SNPs. We randomly
Cancer Causes Control (2015) 26:1603–1616 1607
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split the height allele score into two independent weighted
scores containing 89 and 90 SNPs (for details of the SNPs
in each score see Supplementary Table 3). The height
SNPs were in linkage equilibrium, and hence, these scores
were statistically independent. We estimated the associa-
tion of each instrument with prostate cancer and tested for
heterogeneity [33].
The top eight principal components that reflect the
population’s genetic structure were estimated and included
as covariates in adjusted regression models to account for
confounding by population stratification. We also report
the associations of the genetic risk scores with survival
additionally adjusted for PSA level, grade, and stage. We
ran all statistical analyses in Stata version 13.1 (StataCorp
LP, 2014, College Station, TX).
Results
Our sample consisted of 20,848 cases and 20,214 controls
of European genetic descent, with genotypic data from the
iCOGs array that had passed quality control and was not
included in the GIANT consortium used to generate the
genetic risk scores (EPIC-Norfolk, CAPS, and SEARCH
studies) (Table 1). The percentage of high-grade cancers
reported varied between studies (3.6–35.0 %), as did the
proportion of advanced stage cancers (3.5–64.5 %). The
case-only survival analysis was based on 15,491 men,
because 5,357 of the 20,848 men with prostate cancer did
not have age at entry or exit in the dataset.
Associations of genetic risk scores with measured
height and BMI in ProtecT
Associations of the weighted genetic risk scores with
height and BMI in the ProtecT sub-sample are shown in
Table 2. The results with the unweighted score were sim-
ilar, but less precise (results not shown). The genetic risk
scores explained 6.31 and 1.46 % of the variability in
height and BMI, respectively, consistent with previous
studies [23, 24], which suggest that the genetic risk scores
are strong instruments for the phenotypes.
Associations of genetic risk scores with potential
confounders in ProtecT
Taller men were more likely to have managerial jobs, have
lower PSA levels, and have joined the ProtecT study at a
younger age (Table 3), but there was little evidence that the
height genetic risk score was associated with any of the
confounders except benign hypertrophy of the prostate (all
p values[0.05). Heavier men were more likely to have
diabetes; be inactive; drink fewer than 3 drinks a week; be
a nonsmoker; and have lower IGF-I levels (Table 3), but
we found little evidence that the BMI genetic risk score
was associated with any of the potential confounders (all
p values[0.05).
Association of the genetic risk scores and prostate
cancer risk and mortality
Associations of the genetic risk scores for height and BMI
with prostate cancer risk are shown in Table 4, with the
study-specific estimates in Supplementary Figures 1–10.
There was little consistent evidence that the genetic risk
score for height was associated with prostate cancer,
although there was weak evidence of an inverse association
with advanced prostate cancer [OR, per standard deviation
increase in height genetic score 0.96; 95 % CI 0.93, 0.99,
p = 0.01; p heterogeneity, advanced vs. localized 0.05].
There was weak evidence that the genetic risk score for BMI
was associated with a reduced prostate cancer risk (OR per
standard deviation increase in BMI genetic score 0.98; 95 %
CI 0.96, 1.00; p = 0.07), but little evidence of variation by
stage or grade (p heterogeneity 0.64 and 0.13, respectively).
The height genetic risk score was associated with an
increase in prostate cancer-specific mortality among men
with low-grade disease (OR per standard deviation increase
in the height score 1.13; 95 % CI 1.08, 1.20, p hetero-
geneity, low vs. high grade\0.001), but there was little
evidence of associations with all-cause mortality (Table 5).
The BMI genetic risk score was associated with higher all-
cause mortality among low-grade disease (OR per standard
deviation increase in the BMI score 1.08; 95 % CI 1.03,
1.14, p heterogeneity low vs. high grade = 0.03), but there
was little evidence of associations with prostate cancer-
specific mortality.
Table 2 Association of
weighted height and BMI
genetic risk scores with
measured height and weight in
907 controls in ProtecT [28]
n Mean difference 95 % CI r2 (%) F-statistic
Lower limit Upper limit
Height 907 0.26 0.20 0.33 6.31 67.6
BMI 901 0.12 0.06 0.19 1.46 13.6
To allow direct comparison of effect sizes, BMI and height phenotypic measurements and the genetic risk
scores were normalized to mean zero and standard deviation one
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Table 3 Odds ratio or change in continuous variable covariates per standard deviation change in either height and BMI (phenotypes) or genetic
risk scores for height and BMI (instruments) in the ProtecT study cases [28]
n Observed phenotypea Genetic risk scoresa
Effect
estimate
Confidence intervalb p value Effect
estimate
Confidence intervalb p value
Lower Upper Lower Upper
Standardized height Odds ratioc Odds ratioc
Binary variables
Diabetes 726 0.91 0.64 1.30 0.62 0.94 0.70 1.25 0.66
Managerial occupation 818 1.21 1.06 1.40 0.006 0.91 0.79 1.04 0.17
Strenuous exercise 621 1.13 0.96 1.33 0.13 1.03 0.87 1.21 0.75
Moderate or strenuous exercise 621 1.15 0.96 1.37 0.12 1.01 0.85 1.20 0.90
C3 drinks in the last week 820 1.13 0.98 1.30 0.09 1.05 0.91 1.22 0.47
Passive smoker 752 1.03 0.89 1.19 0.72 1.00 0.86 1.16 0.99
Ever smoker 780 1.10 0.95 1.27 0.21 1.08 0.93 1.25 0.33
Current smoker 552 1.09 0.89 1.35 0.40 1.21 0.97 1.51 0.08
Benign hypertrophy of the prostate 704 0.77 0.58 1.02 0.07 1.38 1.01 1.88 0.05
Regression coefficientc Regression coefficientc
Continuous variables
PSA (ng/ml) 828 -1.15 -2.01 -0.29 0.009 -0.31 -1.32 0.70 0.55
IGF-I (ng/ml) 718 1.80 -2.23 5.83 0.38 -2.53 -6.31 1.25 0.19
Age (years) 1,109 -0.53 -0.83 -0.24 \0.001 0.07 -0.23 0.38 0.64
Standardized BMI Odds ratioc Odds ratioc
Binary variables
Diabetes 724 1.90 1.45 2.48 \0.001 1.16 0.86 1.57 0.33
Managerial occupation 813 0.96 0.83 1.10 0.54 0.91 0.79 1.05 0.20
Strenuous exercise 617 0.91 0.77 1.08 0.28 1.05 0.89 1.23 0.57
Moderate or strenuous exercise 617 0.80 0.66 0.96 0.02 1.01 0.85 1.20 0.94
C3 drinks in the last week 814 0.87 0.75 1.01 0.07 0.90 0.78 1.04 0.17
Passive smoker 748 1.12 0.97 1.30 0.13 0.97 0.84 1.12 0.65
Ever smoker 776 1.09 0.93 1.27 0.29 1.09 0.94 1.27 0.25
Current smoker 548 0.71 0.54 0.94 0.02 1.18 0.95 1.48 0.13
Benign hypertrophy of the prostate 700 0.92 0.69 1.23 0.56 0.94 0.71 1.25 0.66
Regression coefficientc Regression coefficientc
Continuous variables
PSA (ng/ml) 822 -0.25 -1.55 1.05 0.70 -0.21 -0.96 0.54 0.58
IGF-I (ng/ml) 714 -5.38 -9.12 -1.64 0.005 1.77 -1.97 5.51 0.35
Age (years) 1,101 -0.28 -0.60 0.04 0.08 -0.04 -0.33 0.25 0.79
a Observed phenotypes and genetic risk scores normalized to mean zero and standard deviation one
b Robust standard errors
c Odds ratio or change in continuous variable per standard deviation change in height and BMI (phenotype or genetic risk score)
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Sensitivity analysis
Prostate cancer risk
There was little evidence that men with height variants
with larger effects on the height phenotype were more or
less likely to be diagnosed with prostate cancer
(r2 = 0.0071) (Fig. 1; see Supplementary Table 4 for
associations of each of the height variants with prostate
cancer risk). There was some evidence that BMI variants
with the largest effect on BMI were most strongly inversely
associated with prostate cancer (r2 = 0.0231) (Fig. 2;
Supplementary Table 5 for associations of each of the BMI
variants with prostate cancer risk). We found little evi-
dence of heterogeneity in the effect of BMI proxied by
independent instruments based on independent genetic
scores made up of different sets of SNPs. Individuals with
more BMI increasing FTO alleles were less likely to be
diagnosed with prostate cancer (OR per BMI increasing
allele rs1558902-A 0.97; 95 % CI 0.94, 1.01, p = 0.10). In
line with this, the allele score based on the remaining 31
BMI SNPs was also inversely associated with prostate
cancer (OR per standard deviation increase in BMI genetic
score excluding FTO 0.99; 95 % CI 0.97, 1.01, p = 0.33;
p value for heterogeneity between the two independent
instruments = 0.38).
All-cause mortality
There was little evidence that the two sets of independent
height or BMI allele scores were associated with an
increased risk of all-cause mortality in men diagnosed with
prostate cancer (see Supplementary Table 10 for associa-
tions of all 179 height SNPs and all-cause mortality and
Supplementary Table 7 for associations of each of the 32
BMI SNPs with all-cause mortality and prostate cancer-
specific mortality).
Prostate cancer-specific mortality
Both sets of independent height allele scores were associ-
ated with an increased risk of prostate cancer-specific
mortality in men diagnosed with low-grade prostate cancer
(hazard ratio per one standard deviation increase in the first
height allele score 1.10; 95 % CI 1.03, 1.19, p = 0.008;
and in the second height allele score 1.09; 95 % CI 1.05,
1.13, p\ 0.001; p value for heterogeneity = 0.86; see
Table 4 Odds ratio of prostate cancer per one standard deviation change in height or BMI genetic score
n Unadjusted Adjusteda
Odds
ratioc
Confidence
intervalb
p value Odds
ratioc
Confidence
intervalb
p value p heterogeneityd
Lower Upper Lower Upper
Height
Controls 20,214 1.00 – – – 1.00 – – – –
All prostate cancers 20,848 0.96 0.91 1.01 0.12 0.99 0.97 1.01 0.23
Localized prostate cancer 12,975 0.96 0.88 1.03 0.27 1.00 0.98 1.02 0.72 0.05
Advanced prostate cancer 4,325 0.90 0.83 0.98 0.02 0.96 0.93 0.99 0.01
Low-grade prostate cancer 8,784 0.96 0.90 1.02 0.20 0.99 0.96 1.01 0.30 0.55
High-grade prostate cancer 8,230 0.97 0.92 1.02 0.26 1.00 0.98 1.02 0.85
BMI
Controls 20,214 1.00 – – – 1.00 – – – –
All prostate cancers 20,848 0.98 0.96 1.01 0.15 0.98 0.96 1.00 0.07
Localized prostate cancer 12,975 0.98 0.96 1.00 0.10 0.98 0.96 1.00 0.05 0.64
Advanced prostate cancer 4,325 1.01 0.97 1.05 0.69 1.01 0.97 1.05 0.62
Low-grade prostate cancer 8,784 0.98 0.94 1.02 0.25 0.97 0.94 1.00 0.09 0.13
High-grade prostate cancer 8,230 1.00 0.97 1.02 0.69 1.00 0.98 1.01 0.65
a Adjusted for the eight principal components of population stratification
b Based in robust standard errors to account for within-study clustering
c Change in odds ratio per standard deviation change in height and BMI genetic risk score (standardized to mean zero standard deviation one)
d Localized versus advanced, or high- versus low-grade using multivariate logistic regression
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Supplementary Table 8 for the association of prostate
cancer-specific mortality and each of the 179 height SNPs).
None of the BMI independent instruments or individual
SNPs were associated with prostate cancer-specific mor-
tality (Supplementary Table 9). Further adjusting the
associations of the genetic risk scores and survival for PSA
level, grade, and stage made no substantial differences to
the results (Supplementary Table 10).
Discussion
We found weak evidence that genetically elevated BMI
was associated with a reduced risk of prostate cancer, but
that genetically elevated height was not associated with
prostate cancer risk. The height and BMI allele scores were
positively associated with prostate cancer-specific and all-
cause mortality, respectively, but only among men with
low-grade disease (p heterogeneity, low- vs. high-grade
prostate cancer\0.05).
Although evidence for these associations was relatively
weak, the inverse relationship of BMI with prostate cancer
risk is in line with both observational data [8] and our
previous genetic study [15]. The latter report showed an
inverse relationship of a single obesity-related SNP (FTO
rs9939609) with overall- and low-grade prostate cancer in
ProtecT, a much smaller population-based sample of 1,550
screen-detected prostate cancers and 1,815 controls [15].
We found inverse associations of a related SNP in FTO
(rs1558902, which is in linkage disequilibrium with
Table 5 Hazard ratio of all-cause and prostate cancer-specific mortality among men with prostate cancer per one standard change in height or
BMI genetic score
Number of
participants
Number
of
failures
Years at
risk
(1000s)
Unadjusted Adjusteda
Hazard
ratioc
Confidence
intervalb
p value Hazard
ratioc
Confidence
intervalb
p value p heterogeneityd
Lower Upper Lower Upper
All-cause mortality
Height
All cases 14,649 3,591 105 1.02 0.97 1.08 0.47 1.00 0.96 1.04 0.88
Localized 8,553 1,447 65 1.01 0.93 1.09 0.81 1.00 0.93 1.07 0.97 0.20
Advanced 3,435 1,332 25 1.08 0.98 1.18 0.11 1.07 0.99 1.14 0.07
Low grade 5,684 905 43 1.04 0.97 1.11 0.32 1.02 0.95 1.09 0.57 0.80
High grade 5,892 1,365 36 1.02 0.97 1.08 0.36 1.01 0.96 1.06 0.71
BMI
All cases 14,649 3,591 105 1.02 0.99 1.05 0.18 1.02 0.99 1.05 0.23
Localized 8,553 1,447 65 1.04 0.99 1.10 0.09 1.04 0.99 1.10 0.09 0.28
Advanced 3,435 1,332 25 1.01 0.98 1.04 0.50 1.01 0.98 1.05 0.59
Low grade 5,684 905 43 1.09 1.04 1.15 0.001 1.08 1.03 1.14 0.002 0.03
High grade 5,892 1,365 36 1.00 0.96 1.05 0.89 1.00 0.95 1.05 0.98
Prostate cancer-specific mortality
Height
All cases 14,649 1,483 105 1.02 0.98 1.06 0.44 1.00 0.97 1.04 0.87
Localized 8,553 363 65 0.98 0.91 1.07 0.72 0.99 0.91 1.08 0.79 0.29
Advanced 3,435 745 25 1.05 1.00 1.10 0.06 1.04 1.00 1.09 0.07
Low grade 5,684 188 43 1.13 1.06 1.21 \0.001 1.13 1.08 1.20 \0.001 \0.001
High grade 5,892 678 36 0.97 0.93 1.02 0.20 0.97 0.93 1.01 0.19
BMI
All cases 14,649 1,483 105 0.99 0.96 1.03 0.76 1.00 0.96 1.04 0.94
Localized 8,553 363 65 0.95 0.88 1.03 0.22 0.95 0.87 1.05 0.31 0.09
Advanced 3,435 745 25 1.04 0.98 1.10 0.18 1.05 0.99 1.10 0.11
Low grade 5,684 188 43 0.95 0.89 1.01 0.08 0.95 0.88 1.01 0.12 0.03
High grade 5,892 678 36 1.05 0.99 1.11 0.12 1.05 0.98 1.13 0.14
a Adjusted for the first eight principal components of population stratification
b Based in robust standard errors to account for within-study clustering
c Change in hazard ratio per standard deviation change in height and BMI genetic risk score (standardized to mean zero standard deviation one)
d Localized versus advanced, or high- versus low-grade using Bland–Altman tests
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rs9939609 at r2 = 0.90) with overall and low-grade pros-
tate cancer risk (individuals with more BMI increasing
alleles had a reduced risk of all prostate cancer and low-
grade prostate cancer, respectively (OR 0.97; 95 % CI
0.94, 1.00; p = 0.10, and OR 0.95; 95 % CI 0.90, 1.00;
p = 0.06). A previous study that created genetic risk scores
for BMI using 24 of the 32 SNPs from the BMI GWAS
[36] observed ORs for the BMI risk scores of 1.00 (95 %
CI 0.97, 1.04; p = 0.94) for the unweighted score and 1.07
(95 % CI 0.91, 1.25; p = 0.41) for the weighted score, but
the effect estimates were imprecise as the study only
included 871 cases and 906 controls.
To determine whether our findings reflect clinically
important differences in disease risk, we rescaled the
results to report the effects of one standard deviation
changes in height and one kg/m2 increases in BMI using
the coefficients for the effects of the SNPs on height and
BMI reported by Lango Allen et al. [23] and Speliotes et al.
[24], respectively. Our results imply that a one standard
deviation increase in height was associated with a 49 %
(95 % CI 26 %, 76 %, p\ 0.001) increase in prostate
cancer mortality among those with low-grade disease,
assuming that the height allele score explains 10 % of the
variation in height [23]. A 1 kg/m2 increase in BMI was
associated with a 4 % (95 % CI 0 %, 8 %, p = 0.07)
reduced risk of any prostate cancer diagnosis (assuming
that the BMI allele score explains 1.45 % of the variation
in BMI [24] and a standard deviation of BMI of 3.5 kg/m2).
The risk of all-cause mortality was increased by 21 %
(95 % CI 7 %, 37 %) per kg/m2 increase in BMI among
men with low-grade disease.
Our finding that genetic variation in height was not
associated with an increase in prostate cancer risk is in
contrast to the majority of the observational literature [6].
Indeed, we found weak evidence of an inverse association
of genetic variation in height with advanced prostate can-
cer. However, there is some evidence of reporting bias in
the previous literature; 12 of 30 prospective studies that
reported effects of height on prostate cancer only in the
body of the manuscript, and which were not highlighted in
the title or abstract, were null (pooled OR 1.01; 0.95–1.07;
I2 0 %) [6]. The absence of a positive association of genetic
variation in height with prostate cancer risk in the current
study may reflect that there is no real effect of height on
prostate cancer risk or that it is the environmental (espe-
cially early-life factors [37, 38]) and not genetic compo-
nent of height variation that explains its positive link in
some studies with incident prostate cancer [16–18, 39].
Alternatively, if height is associated with very early case-
fatality in men with prostate cancer, then this will remove
cases from the pool available for case–control studies and
could theoretically lead to selection bias causing null
findings. However, prostate cancer is not generally so
rapidly fatal as to preclude significant numbers of men
from being included in case–control studies.
The height and BMI allele scores were positively asso-
ciated, respectively, with prostate cancer-specific and all-
cause mortality, but only strongly among men with low-
grade disease. The positive association of BMI and height
with mortality among men with prostate cancer is in line
with earlier studies [9, 11, 40], although previous findings
for height have been inconsistent [41, 42], and one study
observed that taller men with prostate cancer had improved
survival [43]. Our data suggest that only height is associ-
ated with prostate cancer-specific, rather than all-cause,
mortality, and that BMI causes a broader range of deaths
among men with prostate cancer.
The difference in the magnitude of effect estimates by
grade does not appear to have been reported in the past and
could simply be a chance finding. However, the p values
for heterogeneity for the association of the BMI allele score
with all-cause mortality and the height allele score with
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Fig. 1 Scatter plot of effects of SNPs on prostate cancer risk by their
effects on height
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Fig. 2 Scatter plot of effects of SNPs on prostate cancer risk by their
effects on BMI
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prostate cancer-specific mortality by grade were 0.03 and
\0.001, respectively. The findings could, therefore, reflect
differing determinants of progression depending on grade.
This highlights the potential for modifying BMI in people
with low-grade disease; however, it is likely that the
genetic contribution to height explains the association of
the height genetic score with prostate cancer progression.
Such genetic influences could include effects on insulin-
like growth factors (IGFs), which have been associated
with progression of prostate cancer [44].
The strengths of the study include (1) the robust
instruments developed from previous GWAS that
explained a reasonable proportion of the variance in the
phenotypes of interest, (2) the large sample size, and (3) the
potential confounders which were associated with mea-
sured height and BMI within the ProtecT study were not
associated with the genetic risk scores for height and BMI.
The final point suggests that association of genetic risk
scores with prostate cancer outcomes is unlikely to be
explained by confounders. Evidence from genetic variation
is less likely to suffer from biases that affect conventional
observational studies. The generalizability of our findings
is supported by broadly consistent results across the 22
studies. There are limitations to our Mendelian random-
ization approach, and our results could be explained by
bias or confounding. For example, we used combinations
of genome-wide genetic variants to proxy BMI and height,
but these variants may not be specific for BMI or height
and may influence prostate cancer through biological
pathways other than through the phenotypes that they are
acting as proxies for (genetic confounding or pleiotropy).
This is plausible since even single SNPs can exert pleio-
tropic effects across a range of different variables [45]; for
example, many BMI-associated SNPs are present at quite
low levels of significance in a GWAS of c-reactive protein
(CRP) [34]. However, we found similar results when we
used two independent instruments for each phenotype,
suggesting these results may not be due pleiotropy of a
single SNP. We assumed a similar qualitative effect of the
SNPs in our sample as the GIANT consortium, which is
highly plausible but may not be true. We found little evi-
dence that the genetic risk scores were associated with
baseline covariates in the ProtecT study, and this is con-
sistent with findings from the broader literature [46–49].
A reduced risk of prostate cancer associated with BMI is
biologically plausible, with proposed mechanisms includ-
ing the increase in estrogens (aromatase inhibitors) sec-
ondary to adiposity. However, we cannot rule out detection
bias [50] arising from delayed diagnosis and more
advanced stage at diagnosis in obese men; this may arise
due to lower accuracy of digital rectal examination in
obese men or lower PSA values caused by obesity-related
hemodilution [8, 9].
In conclusion, our genetic data provide some evidence
(albeit weak) that an elevated BMI may protect against
prostate cancer risk or reduce the likelihood of it being
detected (in particular, low-grade cancer), but may increase
the likelihood of death in men with low-grade prostate
cancer. These observations support epidemiological find-
ings that obesity protects against a diagnosis of localized
prostate cancer but increases prostate cancer mortality [8].
Previously observed positive associations of height with
prostate cancer risk may reflect the environmental deter-
minants of height. In contrast, observed positive associa-
tions of height with prostate cancer mortality may reflect
the genetic determinants of height or of height determining
phenotypes (e.g., IGF [39]). The findings for mortality that
were only observed among men with low-grade disease are
novel, and potentially clinically important, but do require
replication.
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